Lysosomal malfunction accompanies alpha-synuclein aggregation in a progressive mouse model of Parkinson's disease

Brain Research

Volumn 956, Issue 1, 2002, Pages 156-165

  Meredith, G E ^a   Totterdell, S ^b   Petroske, E ^c   Santa Cruz, K ^e   Callison Jr , R C ^d   Lau, Y S ^c  

^a ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^d UNIVERSITY OF MISSOURI KANSAS CITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

Author keywords

Inclusion body; Lewy body; Lipofuscin; MPTP; Probenecid; Ubiquitin

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ALPHA SYNUCLEIN; LIPOFUSCIN; PROBENECID; PROTEIN; TOXIN; UBIQUITIN;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN CELL; CELL DEATH; CELL FUNCTION; CELL INCLUSION; CONTROLLED STUDY; CYTOPLASM; DOPAMINERGIC SYSTEM; DOWN REGULATION; GENE EXPRESSION; GRANULAR CELL; IMMUNOREACTIVITY; LIMBIC CORTEX; LYSOSOME; MALE; MOUSE; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN DEGRADATION; SOLUBILITY; SUBSTANTIA NIGRA;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ALPHA-SYNUCLEIN; ANIMALS; CELL DEATH; CEREBRAL CORTEX; DOPAMINE AGENTS; GENE EXPRESSION; HUMANS; INCLUSION BODIES; LIPOFUSCIN; LYSOSOMES; MALE; MICE; MICE, INBRED C57BL; MODELS, ANIMAL; NERVE TISSUE PROTEINS; NEURONS; PARKINSON DISEASE; PROBENECID; SYNUCLEINS; TIME FACTORS; UBIQUITIN; URICOSURIC AGENTS;

EID: 0037159608     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(02)03514-X     Document Type: Article

References (52)

1. Arima K., Ueda K., Sunohara N., Hirai S., Izumiyama Y., Tonozuka-Uehara H., Kawai M. Immunoelectron-microscopic demonstration of NACP/α-synuclein-epitopes on the filamentous component of Lewy bodies in Parkinson's disease and in dementia with Lewy bodies. Brain Res. 808:1998;93-100.
2. Barbeau A. Etiology of Parkinson's disease: A research strategy. Can. J. Neurol. Sci. 11:1984;24-28.
3. Beal M.F. Experimental models of Parkinson's disease. Nat. Rev. 2:2001;325-332.
4. Bence N.F., Sampat R.M., Kopito R.R. Impairment of the ubiquitin proteasome system by protein aggregation. Science. 292:2001;1552-1555.
5. Bennett M.C., Bishop J.F., Leng Y., Chock P.B., Chase T.N., Mouradian M.M. Degradation of α-synuclein by proteasome. J. Biol. Chem. 274:1999;33855-33858.
6. Betarbet R., Sherer T.B., MacKenzie G., Garcia-Osuna M., Panov A.V., Greenamyre J.T. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat. Neurosci. 3:2000;1301-1306.
7. Braak E., Sandmann-Keil D., Rub U., Gai W.P., de Vos R.A., Steur E.N., Arai K., Braak H. α-synuclein immunopositive Parkinson's disease-related inclusion bodies in lower brain stem nuclei. Acta Neuropathol. 101:2001;195-201.
8. Brunk U.T. On the origin of lipofuscin; the iron content of residual bodies, and the relation of these organelles to the lysosomal vacuole. A study on cultured human glial cells. Porta E.A., Lipofuscin and Ceroid Pigments. 1990;313-320 Plenum Press, New York.
9. Chadi G., Moller A., Rosen L., Janson A.M., Agnati L.A., Goldstein M., Ogren S.-O., Petersson R.F., Fuxe K. Protective actions of human recombinant basic fibroblast growth factor on MPTP-lesioned nigrostriatal dopamine neurons after intraventricular infusion. Exp. Brain Res. 97:1993;145-158.
10. Clayton D.F., George J.M. Synucleins in synaptic plasticity and neurodegenerative disorders. J. Neurosci. Res. 58:1999;120-129.
11. Cleeter M.W.J., Cooper J.M., Schapira A.H.V. Irreversible inhibition of mitochondrial complex I by 1-methyl-4-phenylpyridinium (MPP+); evidence for free radical involvement. J. Neurochem. 58:1992;786-789.
12. Crowther R.A., Jakes R., Spillantini M.G., Goedert M. Synthetic filaments assembled from c-terminally truncated α-synuclein. FEBS Lett. 436:1998;309-312.
13. Duffy P.E., Tennyson V.M. Phase and electron microscopic observations of Lewy bodies and melanin granules in the substantia nigra and locus coeruleus in Parkinson's disease. J. Neuropathol. Exp. Neurol. 24:1965;398-414.
14. Feany M.B., Bender W.W.A. Drosophila model of Parkinson's disease. Nature. 404:2000;394-398.
15. Forno L.S., DeLanney L.E., Irwin I., Langston J.W. Similarities and differences between MPTP-induced parkinsonism and Parkinson's disease: Neuropathologic considerations. Adv. Neurol. 60:1993;600-608.
16. Forno L.S., DeLanney L.E., Irwin I., Langston J.W. Electron microscopy of Lewy bodies in the amygdala-parahippocampal region: Comparison with inclusion bodies in the MPTP-treated squirrel monkey. Adv. Neurol. 69:1996;217-228.
17. Gunderson H.J. Stereology of arbitrary particleas. A review of unbiased number and size estimators and the presentation of some new ones, In memory of William R. Thompson J. Microsc. 143:1986;3-45.
18. Haas A.L., Bright P.M. The immunochemical detection and quantitation of intracellular ubiquitin-protein conjugates. J. Biol. Chem. 260:1987;12464-12473.
19. Harhangi B.S., Farrer M.J., Lincoln S., Bonifati V., Meco G., De Michele G., Brice Durr A., Martinez M., Gasser T., Bereznai B., Vaughan J.R., Wood N.W., Hardy J., Oostra B.A., Breteler M.M. The Ile93Met mutation in the ubiquitin carboxy-terminal-hydrolase-L1 gene is not observed in European cases with familial Parkinson's disease. Neurosci. Lett. 270:1999;1-4.
20. Harman D. Lipofuscin and ceroid formation: the cellular recycling system. Porta E.A., Lipofuscin and Ceroid Pigments. 1990;3-15 Plenum Press, New York.
21. Hideki S., Schlossmacher M.G., Hattori N., Frosch M.P., Trockenbacher A., Schneider R., Mizuno Y., Kosik K.S., Selkoe D.J. Ubiquitination of a new form of [alpha]-synuclein by parkin from human brain: Implications for Parkinson's disease. Science. 293:2001;263-269.
22. Ikeda K., Akiyama H., Arai T., Kondo H., Haga C., Iritani S., Tsuchiya K. Alz-50/Gallyas-positive lysosome-like intraneuronal granules in Alzheimer's disease and control brains. Neurosci. Lett. 258:1998;113-116.
23. Ischiropoulos H., Zhu L., Chen J., Tsai M., Martin J.C., Smith C.D., Beckman J.S. Peroxynitrite-mediated tyrosine nitration catalyzed by superoxide dismutase. Arch. Biochem. Biophys. 298:1992;431-437.
24. Ivy G.O., Schottler F., Wenzel J., Baudry M., Lynch G. Inhibitors of lysosomal enzymes: accumulation of lipofuscin-like dense bodies in the brain. Science. 226:1984;985-987.
25. Iwai A., Masliah E., Yoshimoto M., Ge N., Flanagan L., Rohan de Silva H.A., Kittel A., Saitoh T. The precursor protein of non-Aβ component of Alzheimer's disease amyloid is a presynaptic protein of the central nervous system. Neuron. 14:1995;467-475.
26. Jellinger K. Cytoskeletal pathology of Parkinsonism and aging brain. Calne D., Crippa D., Comi G., Horowski R., Trabucchi M., Parkinsonism and Aging. 1989;35-56 Raven Press, Ltd, New York.
27. Langston J.W., Forno L.S., Tetrud J., Reeves A.G., Kaplan J.A., Karluk D. Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahyudropyridine exposure. Ann. Neurol. 46:1999;598-605.
28. Lau Y.S., Trobough K.L., Crampton J.M., Wilson J.A. Effects of probenecid on striatal dopamine depletion in acute and long- term 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated mice. Gen. Pharmacol. 21:1990;181-187.
29. Manning-Bog A.B., McCormack A.L., Li J., Uversky V.N., Fink A.L., Di Monte D.A. The herbicide Paraquat causes upregulation and aggregation of α-synuclein in mice. J. Biol. Chem. 277:2001;1641-1644.
30. Maroteaux L., Scheller R.H. The rat brain synucleins; family of proteins transiently associated with neuronal membrane. Mol. Brain Res. 11:1991;335-343.
31. Masliah E., Rockenstein E., Veinbergs I., Mallory M., Hashimoto M., Takeda A., Sagara Y., Sisk A., Mucke L. Dopaminergic loss and inclusion body formation in α-synuclein mice: Implications for neurodegenerative disorders. Science. 287:2000;1265-1269.
32. J Mayer R., Laszlo L., Landon M., Hope J., Lowe J. Ubiquitin, lysosomes, and neurodegenerative diseases. Ann. NY Acad. Sci. 674:1992;149-160.
33. Neystat M., Lynch T., Przedborski S., Kholodilov N., Rzhetskaya M., Burke R.E. α-synuclein expression in substantia nigra and cortex in Parkinson's disease. Movement Dis. 14:1999;417-422.
34. Nixon R.A., Cataldo A.M., Paskevich P.A., Hamilton D.J., Wheelock T.R., Kanaley-Andrews L. The lysosomal system in neurons. Involvement at multiple stages of Alzheimer's disease pathogenesis. Ann. NY Acad. Sci. 674:1992;65-88.
35. Oorschot D.E. Total number of neurons in the neostriatal, pallidal, subthalamic, and substantia nigral nuclei of the rat basal ganglia: A stereological study using the Cavalieri and optical dissector methods. J. Comp. Neurol. 366:1996;580-599.
36. Ostrerova-Golts N., Petrucelli L., Hardy J., Lee J.M., Farer M., Wolozin B. The A53T α-synuclein mutation increases iron-dependent aggregation and toxicity. J. Neurosci. 20:2000;6048-6054.
37. Petersen K., Olesen O.F., Mikkelsen J.D. Developmental expression of α-synuclein in rat hippocampus and cerebral cortex. Neuroscience. 91:1999;651-659.
38. Petroske E., Meredith G.E., Callen S., Totterdell S., Lau Y.-S. Mouse model of parkinsonism: A comparison between subacute MPTP and chronic MPTP/p treatment. Neuroscience. 106:2001;589-601.
39. Przedborski S., Chen Q., Vila M., Giasson B.I., Djaldatti R., Vukosavic S., Souza J.M., Jackson-Lewis V.V., Lee V.M., Ischiropoulos H. Oxidative post-translational modifications of α-synuclein in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease. J. Neurochem. 76:2001;637-640.
40. Roy S., Wolman L. Ultrastructural observations in Parkinsonism. J. Pathol. 99:1969;39-44.
41. Saha A.R., Ninkina N.N., Hanger D.P., Anderton B.H., Davies A.M., Buchman V.L. Induction of neuronal death by α-synuclein. Eur. J. Neurosci. 12:2000;3073-3077.
42. Schneider J.S., Yuwiler A., Markham C.H. Selective loss of subpopulations of ventral mesencephalic dopaminergic neurons in the monkey following exposure to MPTP. Brain Res. 411:1987;144-150.
43. Seniuk N.A., Tatton W.G., Greenwood C.E. Dose-dependent destruction of the coeruleus-cortical and nigral-stratal projections by MPTP. Brain Res. 527:1990;7-20.
44. Sohal R.S., Brunk U.T. Lipofuscin as an indicator of oxidative stress and aging. Porta E.A., Lipofuscin and Ceroid Pigments. 1990;17-26 Plenum Press, New York.
45. Spillantini M.G., Schmidt M.L., Lee V.M., Trojanowski J.Q., Jakes R., Goedert M. Alpha-synuclein in Lewy bodies. Nature. 388:1997;839-840.
46. Tatton W.G., Greenwood C.E., Verrier M.C., Holland D.P., Kwan M.M., Biddle F.E. Different rates of age-related loss for four murine monoaminergic neuronal populations. Neurobiol. Aging. 12:1991;543-556.
47. S. Totterdell, D. Hanger, Y.-S. Lau, G.E. Meredith, The ultrastructural distribution of alpha-synuclein-like protein in normal mouse brain: implications for Parkinson's disease, J. Comp. Neurol. (2002) in press.
48. Van der Putten H., Wiederhold K.H., Probst A., Barbieri S., Mistl C., Danner S., Kauffmann S., Hofele K., Spooren W.P., Ruegg M.A., Lin S., Caroni P., Sommer B., Tolnay M., Bilbe G. Neuropathology in mice expressing human α-synuclein. J. Neurosci. 20:2000;6021-6029.
49. Vila M., Vukosavic S., Jackson-Lewis V., Neystat M., Jakowec M., Przedborski S. α-synuclein up-regulation in substantia nigra dopaminergic neurons following administration of the parkinsonian toxin MPTP. J. Neurochem. 74:2000;721-729.
50. West M.J., Slomianka L., Gundersen H.J. Unbiased stereological estimation of the total number of neurons in the subdivisions of the rat hippocampus using the optical fractionator. Anat. Rec. 231:1991;482-497.
51. Wood S.J., Wypych J., Steavenson S., Louis J.C., Citron M., Biere A.L. α-synuclein fibrillogenesis is nucleation-dependent. J. Biol. Chem. 274:1999;19509-19512.
52. Zhang I., Dawson V.L., Dawson T.M. Oxidative stress and genetics in the pathogenesis of Parkinson's disease. Neurobiol. Dis. 7:2000;240-250.